

Integrin Alpha 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/IFBA742B561EN.html>

Date: August 2019

Pages: 87

Price: US\$ 3,500.00 (Single User License)

ID: IFBA742B561EN

Abstracts

Integrin Alpha 4 - Pipeline Review, H2 2019

SUMMARY

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 3, 4 and 3 respectively.

Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Ophthalmology, Cardiovascular, Genetic Disorders, Musculoskeletal Disorders and Respiratory which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Multiple Sclerosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular

Degeneration, Asthma, Bone Fracture, Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Keratoconjunctivitis Sicca (Dry Eye), Osteonecrosis, Osteoporosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Rheumatoid Arthritis, Secondary Progressive Multiple Sclerosis (SPMS) and Ventricular Septal Defect.

Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development

Antisense Therapeutics Ltd

Biogen Inc

C4X Discovery Holdings Plc

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Holding Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles

AJM-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATL-1102 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
AXR-159 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize Integrin alpha4 and Integrin beta7 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGA4 and ITGB7 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-5232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones

Featured News & Press Releases

Aug 08, 2019: Takeda submits NDA for SC formulation of vedolizumab to treat ulcerative colitis

Aug 01, 2019: Oral Alpha-4-Beta-7 integrin antagonist PN-943 demonstrates sustained dose-related target engagement activity in a multiple ascending dose phase 1 study

Jul 24, 2019: Phase II clinical trial in DMD on track for dosing completion

Jul 22, 2019: Takeda's study of subcutaneous vedolizumab meets primary goal

May 24, 2019: Antisense Therapeutics: Phase II clinical trial in DMD Fully Enrolled

May 22, 2019: Entyvio (vedolizumab) approved in Japan for the treatment of patients with moderately to severely active Crohn's Disease

May 19, 2019: New Exploratory data from VARSITY, the first head-to-head ulcerative colitis biologic study which demonstrated superiority of Vedolizumab to Adalimumab in clinical remission at week 52, presented at 2019 Digestive Disease Week

May 14, 2019: Oral alpha-4-beta-7 integrin antagonist PN-943 demonstrates superior dose-related target engagement activity to PTG-100 in single ascending dose phase 1 study

May 09, 2019: U.S. Food & Drug Administration accepts Takeda's Biologics License Application for a subcutaneous formulation of Vedolizumab (Entyvio) for maintenance therapy in moderately to severely active ulcerative colitis

May 07, 2019: Biogen presents new data on TYSABRI at 71st annual meeting of the American Academy of Neurology (AAN)

May 07, 2019: Protagonist Therapeutics to present preclinical data on PN-943 at Digestive Disease Week conference 2019

Apr 04, 2019: Antisense Therapeutics provides update on its phase II clinical trial in Duchenne Muscular Dystrophy

Apr 01, 2019: European Medicines Agency accepts Takeda's Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn's Disease

Mar 11, 2019: Takeda's Entyvio achieves superior remission than Humira in ulcerative colitis

Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antisense Therapeutics Ltd, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by C4X Discovery Holdings Plc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by EA Pharma Co Ltd, H2 2019
Pipeline by Immunwork Inc, H2 2019
Pipeline by Morphic Holding Inc , H2 2019
Pipeline by Protagonist Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Antisense Therapeutics Ltd
Biogen Inc
C4X Discovery Holdings Plc
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Holding Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd

I would like to order

Product name: Integrin Alpha 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/IFBA742B561EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IFBA742B561EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970